aid: ai-therapeutics
name: AI Therapeutics
description: >-
  AI Therapeutics (now Orphai Therapeutics) is a clinical-stage biopharmaceutical company founded in
  Guilford, Connecticut by Jonathan Rothberg as LAM Therapeutics, renamed AI Therapeutics, and renamed
  again to OrphAI Therapeutics in September 2023. It built an internal deep-learning platform that
  synthesized public and proprietary drug and disease data to match existing chemical entities to new
  indications, and used it to advance a rare-disease and pulmonary pipeline — LAM-001, an inhaled
  formulation of sirolimus (rapamycin) targeting mTOR-driven pulmonary disease, plus the earlier
  PIKfyve inhibitor programs LAM-002 and LAM-003. Quince Therapeutics (Nasdaq: QNCX) acquired Orphai
  in May 2026 and now runs it as a subsidiary. The AI platform is an internal drug-discovery tool, not
  a product: the company operates no developer program, publishes no API, SDK or machine-readable
  contract, and its public web presence is a single-page corporate site.
url: https://raw.githubusercontent.com/api-evangelist/ai-therapeutics/refs/heads/main/apis.yml
image: https://orphai-therapeutics.com/wp-content/uploads/2026/07/orphai-logo-new.png
x-status: acquired
x-acquired-by: quince-therapeutics
x-acquired-date: '2026-05-18'
x-status-note: >-
  Renamed from LAM Therapeutics to AI Therapeutics, then to OrphAI Therapeutics in September 2023.
  Acquired by Quince Therapeutics (Nasdaq: QNCX) on 2026-05-18 and now operated as a subsidiary; the
  live site orphai-therapeutics.com carries the acquisition announcement and has been reduced to a
  single page.
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-13'
modified: '2026-09-13'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Artificial Intelligence
- Clinical Trials
- Rare Disease
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://orphai-therapeutics.com/
- type: GitHubOrganization
  url: https://github.com/AI-Therapeutics
- type: DomainSecurity
  url: security/ai-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-09-13'
  status: minimal
  artifacts_added: 2
  pass: local-v3
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    AI Therapeutics is a clinical-stage biopharmaceutical company (now Orphai Therapeutics, a Quince
    Therapeutics subsidiary) whose product is an inhaled rapamycin drug candidate, not software — its
    only live host, orphai-therapeutics.com, is a one-page WordPress corporate site that 404s every
    /.well-known/, OpenAPI and llms.txt path, and its GitHub organization has zero public repositories.
  evidence:
  - url: https://orphai-therapeutics.com/.well-known/agent-card.json
    status: 404
  - url: https://orphai-therapeutics.com/openapi.json
    status: 404
  - url: https://orphai-therapeutics.com/llms.txt
    status: 404
  - url: https://api.github.com/users/AI-Therapeutics/repos
    status: 200
  checked: '2026-09-13'